# GIP

## Overview
The GIP gene encodes the gastric inhibitory polypeptide, also known as glucose-dependent insulinotropic polypeptide, which is a significant incretin hormone involved in the regulation of glucose metabolism. This gene is located on chromosome 17q21.32 and is responsible for producing a 42-amino acid peptide hormone that plays a crucial role in enhancing insulin secretion in response to nutrient intake, particularly glucose and fats (hinke2002modulation; Lindquist2022The). The gastric inhibitory polypeptide is synthesized and secreted by intestinal K-cells and acts primarily on pancreatic β-cells to stimulate insulin release, thereby contributing to glucose homeostasis (Baggio2007Biology). Beyond its pancreatic effects, GIP influences lipid metabolism, bone remodeling, and neural functions, highlighting its diverse physiological roles (Baggio2007Biology). The hormone's activity is mediated through its specific receptor, and its function can be affected by genetic variations, which have implications for metabolic disorders such as type 2 diabetes and obesity (Regazzo2020The; Lindquist2022The).

## Structure
The glucose-dependent insulinotropic polypeptide (GIP) is a hormone encoded by the GIP gene, located on chromosome 17q21.32. The primary structure of GIP is a 42-amino acid peptide, initially isolated from pig intestinal mucosa, with minor species variations between pigs and humans (hinke2002modulation; Lindquist2022The). The human GIP gene consists of six exons and five introns, with the mature GIP encoded within exons 3 and 4 (hinke2002modulation).

The secondary structure of GIP is predicted to include an alpha-helical region between residues 10 and 29, which is important for receptor binding (hinke2002modulation; gelling1998structure). This helical structure is crucial for the bioactivity of GIP fragments, as it influences receptor binding and activation (hinke2002modulation).

Post-translational modifications of GIP include amidation of the carboxyl-terminus, which has minor effects on its bioactivity (hinke2002modulation). The N-terminus of GIP is critical for its biological activity, and modifications at this site can significantly affect its function, as seen in the development of DPIV-resistant analogues (hinke2002modulation). The tertiary and quaternary structures of GIP are not explicitly detailed in the available sources.

## Function
The GIP gene encodes the gastric inhibitory polypeptide, also known as glucose-dependent insulinotropic polypeptide, which is a crucial incretin hormone involved in glucose metabolism. GIP is synthesized and secreted by intestinal K-cells located primarily in the duodenum and proximal jejunum in response to nutrient ingestion, particularly glucose and fat (Baggio2007Biology). It enhances glucose-dependent insulin secretion by binding to its specific receptor on pancreatic β-cells, leading to increased cAMP levels, inhibition of KATP channels, elevated intracellular Ca2+, and stimulation of insulin exocytosis (Baggio2007Biology). GIP also up-regulates insulin gene transcription and biosynthesis, and influences the expression of components of β-cell glucose sensors (Baggio2007Biology).

Beyond its role in the pancreas, GIP has significant actions in extrapancreatic tissues. It improves glucose tolerance, enhances insulin sensitivity, and influences lipid metabolism by stimulating fatty acid synthesis and re-esterification in adipose tissue (Baggio2007Biology). GIP is also involved in bone remodeling by increasing bone mineral density and affecting bone formation markers (Baggio2007Biology). In the central nervous system, GIP contributes to neural progenitor cell proliferation and behavior modification (Baggio2007Biology).

## Clinical Significance
Mutations and alterations in the expression of the GIP gene have significant clinical implications, particularly in metabolic disorders such as type 2 diabetes and obesity. Missense variants in the GIP gene can affect the hormone's structural and functional architecture, influencing glucose homeostasis and lipid metabolism. These mutations are associated with variations in body mass index (BMI) and may contribute to obesity (Lindquist2022The). In type 2 diabetes, the insulinotropic effect of GIP is impaired, which affects insulin secretion and glucose control (Lindquist2022The).

High circulating levels of GIP are linked to obesity, and GIP receptor (GIPR) knock-out mouse models show resistance to diet-induced obesity, indicating a role in weight regulation (Lindquist2022The). In obesity, GIP levels are elevated, but its insulinotropic activity is reduced due to low expression or downregulation of GIPR in adipose tissue (Regazzo2020The). The GIP/GIPR axis is also implicated in endocrine tumors, where ectopic GIPR expression has been observed, potentially contributing to tumor development and offering targets for therapeutic strategies (Regazzo2020The). These findings underscore the importance of GIP in metabolic and endocrine pathologies.


## References


[1. (Lindquist2022The) Peter Lindquist, Lærke Smidt Gasbjerg, Jacek Mokrosinski, Jens Juul Holst, Alexander Sebastian Hauser, and Mette Marie Rosenkilde. The location of missense variants in the human gip gene is indicative for natural selection. Frontiers in Endocrinology, June 2022. URL: http://dx.doi.org/10.3389/fendo.2022.891586, doi:10.3389/fendo.2022.891586. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2022.891586)

2. (hinke2002modulation) Simon Amadeus Hinke. Modulation of insulinotropic hormone bioactivity with a focus on clucose-dependent insulinotropic polipeptide (GIP) and its receptor. PhD thesis, University of British Columbia, 2002. This article has 0 citations.

[3. (Regazzo2020The) Daniela Regazzo, Mattia Barbot, Carla Scaroni, Nora Albiger, and Gianluca Occhi. The pathogenic role of the gip/gipr axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. Reviews in Endocrine and Metabolic Disorders, 21(1):165–183, January 2020. URL: http://dx.doi.org/10.1007/s11154-019-09536-6, doi:10.1007/s11154-019-09536-6. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11154-019-09536-6)

[4. (Baggio2007Biology) Laurie L. Baggio and Daniel J. Drucker. Biology of incretins: glp-1 and gip. Gastroenterology, 132(6):2131–2157, May 2007. URL: http://dx.doi.org/10.1053/j.gastro.2007.03.054, doi:10.1053/j.gastro.2007.03.054. This article has 2704 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1053/j.gastro.2007.03.054)

5. (gelling1998structure) Richard Wayne Gelling. Structure-function studies of the gastric inhibitory polypeptide/glucose dependent insulinotropic polypeptide (GIP) receptor. PhD thesis, University of British Columbia, 1998. This article has 4 citations.